Clinical trial NCT03441906: QUEST: QUality of Life and Experiences of Sarcoma Trajectories
Official title: QUEST: QUality of Life and Experiences of Sarcoma Trajectories
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Quality of Life
Sarcoma
Diagnostic Interval
Diagnostic Pathway
Care Needs
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
First posted: 2018-02-22
Enrollment: 350
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with sarcoma, see inclusion criteria

Brief summary: Background:

The prognosis of patients with rare cancers in general and sarcomas in particular suffers from delay in diagnosis. Routes to diagnosis for sarcoma need to be quicker and more streamlined, but have neither been studied in detail in larger numbers before, nor in a direct comparison between two countries with different health systems. Comprehensive assessment of diagnostic delays and its determinants, including demographic, clinical, psychosocial and health care system factors, is necessary to improve referral pathways and come to best practice and patient reported outcomes for sarcoma patients.

Research questions to be answered:

This study aims to quantify diagnostic delay (including patient, general practitioner and system delay) and evaluates routes to diagnosis and referral to sarcoma expert centres in the Netherlands and England; to comprehensively evaluate risk factors of diagnostic delay; determine the association between diagnostic delay and outcomes (health-related quality of life, quality-adjusted life years, patient satisfaction, TNM classification, time to local/distant relapse and overall survival); and to assess differences between both countries. This should lead to advices about faster referral where possible.

Detailed description: The researchers will conduct a longitudinal cohort study among all sarcoma patients (≥18 years of age) that will be newly diagnosed in 1.5 years period from October 1st 2017 to March 30st 2019 in one of the participating study centers (5 centers in The Netherlands, 3 centers in England).

Patients will be invited before the start of treatment (with a two months eligibility window) and receive a questionnaire on diagnostic delay, risk factors and patient-reported outcomes. The questionnaire on patient-reported outcomes will be completed again 3 months, 6 months, 1-year and 2 years later.

Data collection will be done within PROFILES, an international registry for cancer patient reported outcomes (www.profilesregistry.nl). Clinical data will be collected through cancer registries and the junior investigator will collect extra data from patients' records.

Eligibility criteria: Inclusion Criteria:

* Age at diagnosis ≥ 18 years
* Diagnosis of sarcoma (histology confirmed by sarcoma histopathologist; according to ICD-10-GM codes C40 and C41 for bone sarcoma and C49 for soft-tissue sarcoma)
* Able to communicate in English (or Dutch)
* Mental capacity to provide informed consent and to participate in the study (as determined by the referring health care professional)
* Patients must be able to complete questionnaires themselves
* Patients must be under treatment or follow-up at one of the participating hospitals.

Exclusion Criteria:

* Too ill to complete questionnaires (according to advice from (former) treating specialist)
* Patients with desmoids fibromatosis will be excluded because of the non-malignancy of the disease; and patients with gastrointestinal stromal tumours (GIST; ICD-10-GM codes C15-20, C26, C48 and C80) will be excluded.

Primary outcomes:
measure: Quality of Life
timeFrame: Baseline
Secondary outcomes:
measure: Diagnostic interval
timeFrame: Relationship between diagnostic interval and quality of life at baseline
measure: Factors influencing diagnostic interval
timeFrame: At baseline
measure: QALY
timeFrame: Baseline
measure: Psychologic impact
timeFrame: 2 years
measure: Change in quality of life
timeFrame: 2 years
measure: PFS
timeFrame: through study completion, an average of 2 years
measure: OS
timeFrame: Through study completion, an average of 2 years
measure: Change in QALY
timeFrame: Change from baseline throughout follow-up of 2 years
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: NKI-AVL
city: Groningen
country: Netherlands
facility: UMCG
city: Leiden
country: Netherlands
facility: LUMC
city: Nijmegen
country: Netherlands
facility: Radboudumc
city: Rotterdam
country: Netherlands
facility: Erasmus medical centre
city: Birmingham
country: United Kingdom
facility: Royal Orthopaedic Hospital
city: London
country: United Kingdom
facility: Royal Marsden NHS Foundation Trust
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
Study officials:
affiliation: Radboud University Medical Center
name: Winette van der Graaf, Prof, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Soomers V, Desar IM, van de Poll-Franse LV, Husson O, van der Graaf WT. Quality of life and experiences of sarcoma trajectories (the QUEST study): protocol for an international observational cohort study on diagnostic pathways of sarcoma patients. BMJ Open. 2020 Oct 26;10(10):e039309. doi: 10.1136/bmjopen-2020-039309.